Repeatability and diurnal variation of eye responses measured with Neuro-Ophthalmic Device (NODe)
Intra-participant repeatability and diurnal variation of eye movements and pupil size response using the Neuro-Ophthalmic Device (NODe) in healthy population
Percy Lazon de la Jara
20 participants
May 4, 2015
Interventional
Conditions
Summary
This is a study designed to determine intra-participant repeatability and diurnal variation of various eye reflexes using a Neuro-Ophthalmic Device (NODe). The NODe is a pre-release, prototype table top imaging device that consists of visual stimulus presentations through a standard tablet (iPAD like) and imaging hardware mounted inside of an enclosure which includes a nose-bridge and a chin-rest for patient alignment. The device intends to test neuro -pathology such as mild traumatic brain injury (mTBI or concussion) by assessing eye movements and pupil reactions in response to different visual stimuli presented on the tablet screen. The aim of this investigation is to determine the repeatability of this device in healthy participants with no previous history of concussion and diurnal variation of eye movements and pupil reaction. The study will be conducted in two phases with each phase including 10 participants. The initial visit will include the participant performing the NODe tests repeatedly for 10 times, while the remaining 6 visits (2 visits per day) will test diurnal variation and will run NODe set of tests once in each visit. The initial visit may take up to 2 hours, while the remaining 6 visits will take up to 15 minutes each to complete. The instrument has not yet been released commercially, but does not contain any components that could potentially cause eye or other injury.
Eligibility
Inclusion Criteria2
- to 60 years of age
- Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent
Exclusion Criteria5
- medically diagnosed psychiatric disorder, with or without current medication
- history of significant head trauma or concussion or any known neurological problem
- medically diagnosed epilepsy or history of seizure
- In the medical examiner’s opinion, be intoxicated (alcohol or drugs) or have had more than 2 standard alcoholic drinks in the 4 hours prior to study visit
- Have undertaken any recreational drugs in the last 48 hours
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The NODe is a pre-release, prototype table top imaging device that consists of visual stimulus presentations through a standard tablet (iPAD like) and imaging hardware mounted inside of an enclosure which includes a nose-bridge and a chin-rest for patient alignment. The device intends to test neuro-pathology such as mild traumatic brain injury (mTBI or concussion) by assessing eye movements and pupil reactions in response to different visual stimuli presented on the tablet screen. The NODe has several features, including a very high frame capture rate that permit acquisition of highly-detailed data on direction of eye gaze and pupil diameter. The operator will instruct the participant on how the NODe exam will occur, including what to expect from the visual stimuli and how long the exam should take. Each test consists of a series of targets that the subject must follow with their gaze or a series of light flashes that will be presented while the participant focuses on a static target. The study will be conducted in two phases with each phase including 10 participants. The initial visit will include the participant performing the NODe tests repeatedly for 10 times, while the remaining 6 visits (2 visits per day) will test diurnal variation and will run NODe set of tests once in each visit. The initial visit may take up to 2 hours, while the remaining 6 visits will take up to 15 minutes each to complete. The visits need not necessarily be on consecutive days, but will be conducted within the time period of a fortnight.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12615000371594